A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
about
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerColon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemopreventionThe Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic AnalysisRole of targeted therapy in metastatic colorectal cancerProtein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.The risk for anemia with targeted therapies for solid tumorsNovel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic reviewThe role of personalized medicine in metastatic colorectal cancer: an evolving landscape.Treatment in advanced colorectal cancer: what, when and how?Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.Making circadian cancer therapy practical.Safety and feasibility of targeted agent combinations in solid tumours.Advances and new perspectives in the treatment of metastatic colon cancer.Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells.Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy.Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.
P2860
Q24563539-AA06E879-368E-40CB-BE57-E972ADAEF723Q26748924-AD492678-A5F4-41F1-BE74-F7AEC7CC6035Q26782809-D7FEA734-F2DD-4FE8-9000-49A617A35D1AQ26797117-EAC4BAB6-F83B-4C28-ACA7-F491A68D3898Q28068817-0D2D1940-0386-435C-B84D-5115E480C72CQ33356339-170424F5-AF79-4587-B12C-295F7FD9686CQ34549722-3BC3189A-71C3-4718-A701-D374D6EF2A9CQ35989994-3CB6D58A-2D6B-4E39-B319-A56928A08DFCQ36337063-C0130225-C334-4F71-8565-60A2AB1CA8F7Q37130603-B74E3281-2329-4204-B707-0E5A8D3F31F9Q37225720-7340B13A-AFD8-44A3-8F4A-81945B1B3381Q37378581-3A46A212-8491-44E5-BFC0-F2DCD63BF5F3Q37561771-3A26145F-7EEE-4B8A-9E49-A202B8B454CEQ37653056-D5F50031-6763-4701-B39F-5DD277087E95Q37665041-573D167E-4182-40AF-A2DC-44DEEAF0F4C5Q38077440-7F7CA38E-7607-4328-AC65-B8EDA5606095Q38229589-1554DB39-C5B9-4505-A6C6-CF5DC632353BQ38666172-7533905C-A2B2-469F-ADD8-EC10517BDEB4Q38838740-D19D9E08-7840-459B-9044-29BFACD5498AQ38941928-E0A04EF2-8A33-4E71-AF5F-4F7E8E897361Q39108067-D958BACF-F59D-4B3B-99F8-9AEC1802C70CQ41008169-816A6671-C47A-4618-9310-A45907856E6FQ41925374-1DD5CD81-7B08-408D-8DEA-8D255AEC7122Q44740671-9548FF9D-4EA7-4308-8DEF-A911FCECBDC4Q46869425-20E40E32-3DCB-4D9B-A1E0-100BB77B7C49Q51581664-892DF9C7-7607-4907-86FE-9881D384EA85Q52362144-0C5120F5-F645-429F-9820-44F05BA24D77Q54537376-8D7CF1C2-95A7-435F-87CB-59EB570D2DFE
P2860
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
A phase II randomized multicen ...... metastatic colorectal cancer.
@en
A phase II randomized multicen ...... metastatic colorectal cancer.
@nl
type
label
A phase II randomized multicen ...... metastatic colorectal cancer.
@en
A phase II randomized multicen ...... metastatic colorectal cancer.
@nl
prefLabel
A phase II randomized multicen ...... metastatic colorectal cancer.
@en
A phase II randomized multicen ...... metastatic colorectal cancer.
@nl
P2093
P50
P356
P1433
P1476
A phase II randomized multicen ...... h metastatic colorectal cancer
@en
P2093
A Comandone
C Carnaghi
C Granetti
M Zuradelli
T Pressiani
P304
P356
10.1093/ANNONC/MDN401
P577
2008-07-30T00:00:00Z